Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Project leader/senior scientist at UniBern.
2 years in pharma industry.
8 years of research activity on the ECS
Full Professor at UniBern.
Collaboration with pharma industry.
10+ years of research activity on the ECS.
Updated: Jun 20, 2019
Synendos Therapeutics was selected among the three finalists at the perfect pitch competition held at the BioTrinity London conference for Europe’s Leading Biopartnering and Investment.
https://www.biotrinity.com/perfectpitch
We are excited to participate in person at this year’s BIO International Convention, in San Diego on June 13-16 2022!
Synendos Therapeutics participates at this year’s virtual edition of the BIO-Europe Digital 2021, October 25-28.
Meeting Synendos Therapeutics Don’t miss the chance to meet Synendos’ CEO Andrea Chicca and talk with him about the novel approach of selective endocannabinoid reuptake inhibitors (SERIs) and the comp